Skip to main content

Table 2 Demographic characteristics and disease severities of propensity score-matched ICU patients with nosocomial pneumonia treated with and without add-on tigecycline in combination regimen

From: Clinical effectiveness of tigecycline in combination therapy against nosocomial pneumonia caused by CR-GNB in intensive care units: a retrospective multi-centre observational study

 

Add-on tigecycline

p value

Yes

No

Case number

102

102

 

Mean age (SD)

71.2 (13.2)

70.7 (16.3)

0.806

Male

63 (61.8%)

67 (65.7%)

0.560

Mean BMI (SD)

22.7 (4.7)

22.4 (3.9)

0.614

Smoking history

37 (36.3%)

38 (37.3%)

0.885

Alcohol consumption

15 (14.7%)

14 (13.7%)

0.841

Isolated pathogens

0.845

 CRAB

87 (85.3%)

86 (84.3%)

 

 CRE

15 (14.7%)

16 (15.7%)

 

Pneumonia types

0.756

 HAP

30 (29.4%)

28 (27.5%)

 

 VAP

72 (70.6%)

74 (72.5%)

 

ICU types

0.219

 Medical ICU

76 (74.5%)

68 (66.7%)

 

 Surgical ICU

26 (25.5%)

34 (33.3%)

 

Comorbidities

 Malignancies

16 (15.7%)

16 (15.7%)

1.000

 Renal insufficiency

10 (9.8%)

15 (14.7%)

0.286

 Chronic lung diseases

19 (18.6%)

18 (17.6%)

0.856

 Diabetes

39 (38.2%)

40 (39.2%)

0.886

 Autoimmune disease

7 (6.9%)

7 (6.9%)

1.000

Intravenous antibiotics

 Colistin

49 (48.0%)

55 (53.9%)

0.401

 Sulbactam

28 (27.5%)

28 (27.5%)

1.000

 Carbapenem

37 (36.3%)

39 (38.2%)

0.772

Antibiotics susceptibility

 Colistin resistance

2 (2.2%)

0

0.497

 Sulbactam resistance

27 (26.5%)

29 (28.4%)

0.754

APACHE II scores (median, IQR)a

23 (17–28)

23 (17–27)

0.945

SOFA scores (median, IQR)

 ICU admission

8 (6–10)

8 (6–11)

0.506

 Pneumonia index date

8 (6–11)

8 (6–11)

0.319

Presenting featuresb

 Septic shock

16 (15.7%)

18 (17.6%)

0.707

 Invasive ventilator

98 (96.1%)

91 (89.2%)

0.097

 PF ratio < 200

32 (31.4%)

34 (33.3%)

0.765

 Dialysisc

12 (11.8%)

14 (13.7%)

0.675

Laboratory results (median, IQR)d

 Leukocytes (× 109 per L)

12.7 (8.2–17.4)

11.2 (6.2–16.0)

0.161

 Albumin (g/dL)

2.6 (2.3–2.8)

2.7 (2.3–3.1)

0.051

 CRP (mg/dL)

8.6 (5.6–14.3)

8.8 (6.3–15.4)

0.531

Tigecycline

–

 Daily dosage

  200 mg

4 (5.1%)

–

–

  100 mg

75 (94.9%)

–

–

 Treatment duration (days)

7 (6–14)

–

–

  1. Data are presented as n (%)
  2. APACHE II Acute Physiology and Chronic Health Evaluation II, BMI body mass index, CRP carbapenem-resistant Pseudomonas aeruginosa, CRAB carbapenem-resistant Acinetobacter baumannii, CRE carbapenem-resistant Enterobacteriaceae, HAP hospital-acquired pneumonia, ICU intensive care unit, IQR interquartile range, IV intravenous, PF ratio PaO2/FiO2 ratio, SD standard deviation, SOFA Sequential Organ Failure Assessment, VAP ventilator-associated pneumonia
  3. aObtained on ICU admission date
  4. bPresence of organ dysfunction on pneumonia index date
  5. cIncluding hemodialysis and continuous venovenous hemofiltration
  6. dObtained on pneumonia index date
Back to article page

Journal of Intensive Care

ISSN: 2052-0492